Subscribe for the newsletter
Mobile Navigation
Subscribe for the Newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Response Letter
Sort By
Newest First
1 / 1
FDA
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII
DURECT Corporation
PR-M08-18-NI-059
Aug 15, 2018
1 / 1
Sign in
